This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lönn, S. Articles by Albanes, D. Search for Related Content PubMed PubMed Citation Articles by Lönn, S. Articles by Albanes, D.

Glioma Risk in Relation to Serum Levels of Insulin-Like Growth Factors

¹ Radiation Epidemiology Branch and ² Nutritional Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland; ³ Cancer Prevention Program, Jewish General Hospital and McGill University, Montreal, Quebec, Canada; and ⁴ Department of Health Promotion and Chronic Disease Prevention, National Public Health Institute, Helsinki, Finland

Requests for reprints: Stefan Lönn, Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Room 7053, 6120 Executive Boulevard, Bethesda, MD 20892-7238. Phone: 301-496-2479; Fax: 301-402-0207. E-mail: Lstefan{at}mail.nih.gov

Several studies have suggested that insulin-like growth factors (IGF) are related to cancer risk. We investigated the associations between serum levels of IGF-I and IGF-binding protein-3 and glioma risk. A nested case-control study was conducted within a cancer prevention study, including 29,133 men (ages 50-69 years). In total, 22 glioma cases and 400 randomly selected controls were included. Serum samples were collected a minimum of 5 years before cancer diagnosis. Serum concentrations were measured using ELISA and divided into tertiles based on measurements among controls. Odds ratios and 95% confidence intervals were calculated using the lowest tertile as the reference category. No statistical association was detected between glioma and IGF-binding protein-3. IGF-I was inversely associated with glioma when comparing the lowest tertile with the other tertiles combined (odds ratio, 0.3; 95% confidence interval, 0.1-0.7). The results encourage future research on IGFs in relation to brain tumors in larger studies. (Cancer Epidemiol Biomarkers Prev 2007;16(4):844–6)

This article has been cited by other articles:

				S. Lonn, N. Rothman, W. R. Shapiro, H. A. Fine, R. G. Selker, P. M. Black, J. S. Loeffler, A. A. Hutchinson, and P. D. Inskip Genetic variation in insulin-like growth factors and brain tumor risk Neuro-oncol, August 1, 2008; 10(4): 553 - 559. [Abstract] [Full Text] [PDF]